3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
5
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Multiple Myeloma
1
Melanoma
1
Laryngeal Neoplasms
1
Hematologic Neoplasms
1
Glioma
1
Genomic Instability
1
Gastrointestinal Neoplasms
1
Erdheim-Chester Disease
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Polymerase Chain Reaction
2
Nicotine
2
Immunohistochemistry
2
Gene Expression Profiling
2
Fluorodeoxyglucose F18
2
Drug Therapy
2
Counseling
2
Bupropion
2
trametinib
1
pembrolizumab
1
motexafin gadolinium
1
fluoromisonidazole
1
dabrafenib
1
cobimetinib
1
Zinc Oxide
1
Vemurafenib
1
Varenicline
1
Tobacco Use Cessation Devices
1
Taxes
1
Rubidium-82
1
Ritonavir
1
Referral and Consultation
1
Radiotherapy
1
Quality of Life
1
Psychiatric Rehabilitation
1
Pemetrexed
1
Patient Reported Outcome Measures
1
Observation
1
Nicotine Replacement Therapy
1
Molecular Diagnostic Techniques
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Laryngeal Neoplasms
×
Vemurafenib
×
Thoracic
×
Clear all
NCT05768178
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled